Development of biosimilaries and biosimilar growth hormone
Keywords:
biosimilar, growth hormone, development, productionAbstract
In this article, an informative presentation was made about the development of biosimilar and biosimilar growth hormone in Europe and the Republic of Moldova following the selection and analysis of 37 bibliographic sources from the PubMed database and from specialized journals. Human growth hormone was approved by the EMA in 2006 as the world’s first biosimilar drug. Recombinant growth hormone therapy is currently approved for growth hormone defi ciency, Turner syndrome, chronic kidney failure, in children/adolescents born young for gestational age and Prader-Willi syndrome. At the same time, biosimulation therapy is very expensive. In the Republic of Moldova but also in Eastern Europe, the accessibility of biological medicines is extremely low due to the lack of local or regional producers. The development of the biosimilar production branch, including the biosimilar growth hormone in the Republic of Moldova, will be an attractive and pharmacoeconomically advantageous option for the therapeutic arsenal.
References
1. Allocati E., Bertele V., Gerardi C., Garattini S. Clinical evidence supporting the marketing authorization of biosimilars in Europe. Eur J Clin Pharmacol, 2020, 76(4), 557-566. https://doi.org/10.1007/s00228-019-02805-y
2. Al-Sabbagh A., Olech E., Mcclellan J., Kirchhoff C. Development of biosimilars. Semin Arthritis Rheum, 2016, 45(5 Suppl), 11-18. https://doi.org/10.1016/j.semarthrit.2016.01.002
3. Bonovas S., Peyrin-Biroulet L., Danese S. Clinical development of biologicals and biosimilars - safety concerns. Expert Rev Clin Pharmacol, 2017, 10(6), 567-569. https://doi.org/10.1080/17512433.2017.1293522
4. Bui L., Hurst S., Finch G., Ingram B., Jacobs I., Kirchhoff C. Key considerations in the preclinical development of biosimilars. Drug Discov Today, 2015, nr. 20, 3-15. https://doi.org/10.1016/j.drudis.2015.03.011
5. Cauchy M., Heff ord M. Excipient exchange in the comparison of preparations of the same biologic made by diff erent manufacturing processes: an exploratory study with recombinant human growth hormone (rhGH). Biologicals, 2010, 38(6), 637-643. https://doi.org/10.1016/j.biologicals.2010.07.005
6. Covic A., Kuhlmann M. Biosimilars: recent developments. Int Urol Nephrol, 2007, 39(1), 261-266. https://doi.org/10.1007/s11255-006-9167-5
7. Höybye C., Beck-Peccoz P., Murray R., Simsek S., Stalla G. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone defi ciency: results from an international, post-marketing surveillance study. Pituitary, 2021, 24(4), 622-629. https://doi.org/10.1007/s11102-021-01139-2
8. Ishii-Watabe A., Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metab Pharmacokinet, 2019, 34(1), 64-70. https://doi.org/10.1016/j.dmpk.2018.11.004
9. Lavakumar R., Alyson P., Bojan D. Connectivity maps for biosimilar drug discovery in venoms: the case of Gila monster venom and the anti-diabetes drug Byetta. Toxicon, 2013, nr. 69, 160-167. https://doi.org/10.1016/j.toxicon.2013.03.018
10. Li E, Abbas R, Jacobs I, Yin D. Considerations in the early development of biosimilar products. Drug Discov Today, 2015, nr. 20, Suppl 2, 1-9. https://doi.org/10.1016/j.drudis.2014.12.017
11. López-Siguero J., Pfäffl e R., Chanson P., Szalecki M. Ten years' clinical experience with biosimilar human growth hormone: a review of effi cacy data. Drug Des Devel Ther, 2017, 16, 1489-1495. https://doi.org/10.2147/DDDT.S130320
12. Martin W. Therapy with recombinant growth hormone. MMW Fortschr Med, 2007, 149(23), 41-43. https://doi.org/10.1007/BF03365078
13. Meena S. Clinical development of biosimilars: an evolving landscape. Bioanalysis, 2013, 5(5), 575-586. https://doi.org/10.4155/bio.13.5
14. Mysler E. Biosimilars: clinical interpretation and implications for drug development. Curr Rheumatol Rep, 2015, 17(2) p. 8. https://doi.org/10.1007/s11926-014-0483-y
15. Nabhan Ch., Mato A., Feinber B. Biosimilars in Oncology in the United States: A Review. JAMA Oncol, 2018, 4(2), 241-247. https://doi.org/10.1001/jamaoncol.2017.2004
16. Oliveira Ascef B., Freitas Lopes A., Coelho De Soárez P. Health technology assessment of biosimilars worldwide: a scoping review. Health Res Policy Syst, 2020, vol. 26, nr. 18(1), p. 95. https://doi.org/10.1186/s12961-020-00611-y
17. Oza B., Radhakrishna S., Pipalava P., Jose V. Pharmacovigilance of biosimilars - Why is it diff erent from generics and innovator biologics? J Postgrad Med, 2019, 65(4), 227-232. https://doi.org/10.4103/jpgm.JPGM_109_19
18. Pavlovic M., Girardin E., Kapetanovic L., Ho K. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res, 2008, 69(1), 14-21. https://doi.org/10.1159/000111790
19. Pekka K., Leon Van A., Elena W., Thijs G. Interchangeability of Biosimilars: A European Perspective. BioDrugs, 2017, 31(2), 83-91. https://doi.org/10.1007/s40259-017-0210-0
20. Perpoil A., Grimandi G., Birklé S., Simonet J., Chiffoleau A. Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant? Int J Environ Res Public Health, 2020, 18(1), p. 186. https://doi.org/10.3390/ijerph18010186
21. Pfäffl e R., Bidlingmaier M., Kreitschmann-Andermahr I., Land C. Safety and Eff ectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study. Horm Res Paediatr, 2020, 93(3), 154-163. https://doi.org/10.1159/000508190
22. Rais I. When two do the same, it is not the same. Requirements for development and quality of biosimilars. Pharm Unserer Zeit, 2012, 41(6), 453-460. https://doi.org/10.1002/pauz.201200491
23. Romer T., Peter F., Saenger P., Starzyk J., Koehler B., Korman E., Walczak M. Effi cacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest, 2007, 30(7), 578-89. https://doi.org/10.1007/BF03346352
24. Saenger P. Biosimilar growth hormone. Indian J Pediatr. 2012, 79(1), 92-98. https://doi.org/10.1007/s12098-011-0610-y
25. Saenger P. Current status of biosimilar growth hormone. Int J Pediatr Endocrinol, 2009, 370-379. https://doi.org/10.1186/1687-9856-2009-370329
26. Saenger P. Ten years of biosimilar recombinant human growth hormone in Europe. Drug Des Devel Ther, 2017, 11, 1505-1507. https://doi.org/10.2147/DDDT.S130317
27. Schellekens H. When biotech proteins go off -patent. Trends Biotechnol, 2004, 22(8), 406-410. https://doi.org/10.1016/j.tibtech.2004.06.003
28. Schiestl M., Zabransky M., Sörgel F. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug Des Devel Ther, 2017, nr. 11, 1509-1515. https://doi.org/10.2147/DDDT.S130318
29. Shashank R. Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India, 2018, 44-47.
30. Soldatov A., Avdeeva J., Kryuchkov N., Skosyreva E. Safety concerns of biosimilar hormone products. Curr Med Res Opin, 2019, 35(6), 1003-1009. https://doi.org/10.1080/03007995.2018.1552041
31. Sreedhar S., Hillel P., Gillian R. Pharmacovigilance of Biologics in a Multisource Environment. J Manag Care Spec Pharm, 2017, 23(12), 1249-1254. https://doi.org/10.18553/jmcp.2017.23.12.1249
32. Stergiopoulos S., Brown A., Grampp G., Thomas F. Identifying and Quantifying the Accuracy of Product Name Attribution of US-Sourced Adverse Event Reports in MedWatch of Somatropins and Insulins. Ther Innov Regul Sci, 2015, 49(5), 706-716. https://doi.org/10.1177/2168479015578156
33. Tamilvanan S., Livingston N., Biswanath S. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. J Drug Target, 2010, 18(7), 489-498. https://doi.org/10.3109/10611861003649746
34. Toff oletto O., Afi une J., Thiemann J., Khandave S. Comparative pharmacokinetic and pharmacodynamic evaluation between a new biosimilar and reference recombinant human growth hormone. Growth Horm IGF Res, 2016, nr. 30-31, 31-36. https://doi.org/10.1016/j.ghir.2016.09.003
35. Zelenetz A., Becker P. The Role of Biosimilars. J Natl Compr Canc Netw, 2016, 14(5 Suppl), 626-629. https://doi.org/10.6004/jnccn.2016.0178
36. Webster Ch., Wong A., Woollett G. An Effi cient Development Paradigm for Biosimilars. BioDrugs, 2019, 33(6), 603-611. https://doi.org/10.1007/s40259-019-00371-4
37. Wolff -Holz E., Tiitso K., Vleminckx C., Weise M. Evolution of the EU Biosimilar Framework: Past and Future. BioDrugs, 2019, 33(6), 621-63 https://doi.org/10.1007/s40259-019-00377-y
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
